Stockwinners Market Radar for May 27, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:33 EDT Akerna to implement plan to reduce workforce - Akerna announced that the company is implementing a plan to reduce its workforce and operating costs in order to focus its resources, accelerate its path to profitability, and create stakeholder value. The company anticipates reporting $690,000 in total costs in its second quarter to implement the reduction in force, including the following cost elements: $630,000 in severance and associated payroll taxes; $40,000 in legal costs; and $20,000 in employee insurance benefits. Of the total cost, $440,000 in salaries, payroll taxes and benefits costs would have been reported in its second quarter if the reduction in force had not been implemented. "Our sales performance in 2022 has thus far met our expectations. We believe we are showing signs of progress with revenue now at a run rate of $27m at last filing," commented Jessica Billingsley, Akerna's Chief Executive Officer. "While we believe we can continue to grow revenue and continue to reduce expenses over time, we have made the decision to focus our initiatives on our enterprise business and new market expansion of our SMB business, at least until the market conditions and the regulatory environment are in more favorable territory. We can see a path to positive cash flows and profitability, and the board and the management team are committed to getting there on an accelerated timetable. While we continue to deal with liquidity concerns, our headcount reduction and additional cost savings measures represent a material annual cost savings. As part of this restructure, executive leadership team has also collectively agreed to a 25% reduction in salary to help support the company's cost savings initiatives. As we noted on our last earnings call, bookings have been strong and our CARR is $21.1 million, and we are looking to continue to grow our top-line through a combination of enterprise wins as well as the opportunity we see in new market expansion from the SMB side of the business," added Ms. Billingsley.

17:17 EDT Raytheon Technologies awarded $624.6M Army contract modification - Raytheon was awarded a $624.6M modification to contract for the procurement of Stinger missiles and associated equipment. Work locations and funding will be determined with each order, with an estimated completion date of June 30, 2026. U.S. Army Contracting Command is the contracting activity.

16:35 EDT JinkoSolar subsidiary signs new distribution agreement in Latin America - JinkoSolar announced that its principal operating subsidiary, Jinko Solar Co. has signed a new distribution agreement in Latin America with Aldo Solar. Aldo Solar, which stands out as the largest distributor of solar energy solutions in the country with a market share of approximately 30% in the Distributed Generation segment, will bring to market the new N-Type ultra-efficiency photovoltaic Tiger Neo modules from JinkoSolar. At the end of last year, the companies announced the signing of the largest distribution agreement for distributed generation ever signed by Jinko Solar outside China. And now, this new agreement with Aldo Solar makes Brazil the first market in Latin America to make JinkoSolar 's new N-type modules available and marks the signing of the world's largest contract for the distribution of N-type ultra-efficiency photovoltaic modules from the Tiger Neo family of JinkoSolar. Under this agreement, approximately 600 MW of power from the Tiger Neo family is expected to be distributed. The new panels are expected to be available at Aldo Solar for pre-sale starting in July.

16:29 EDT Nvidia recommends shareholders reject 'mini-tender' offer from Tutanota - Nvidia announced that it recently became aware of an unsolicited "mini-tender" offer by Tutanota to purchase up to 215,000 shares of Nvidia common stock, representing significantly less than 1% of Nvidia's outstanding common stock. The offer price of $210 per share is conditioned on, among other things, the closing price per share of Nvidia's common stock exceeding $210 per share on the last trading day before the offer expires. This means that unless Tutanota waives this condition, Nvidia stockholders who tender their shares in the offer will receive a below-market price. Nvidia cautions stockholders that Tutanota has stated it expects to extend the offer for successive periods of 45 to 180 days, in which case payment would be delayed beyond the scheduled expiration date of Friday, May 27. There is no guarantee that the conditions of the offer will be satisfied. Nvidia recommends that stockholders do not tender their shares in response to Tutanota's offer because the offer requires that the closing price per share of Nvidia's common stock exceed the offer price, and the offer is subject to numerous additional conditions, including Tutanota obtaining financing for the offer. Stockholders who have already tendered their shares may withdraw them at any time by providing notice in accordance with the Tutanota offering documents prior to the expiration of the offer, which is currently scheduled for 5 p.m. Eastern Daylight Time on Friday, May 27.

16:17 EDT PointsBet reports outage in New Jersey until Monday - The company tweeted: "Unfortunately, PointsBet's app will be unavailable in New Jersey until Monday. Please reach out to service@pointsbet.com if you have any further questions. We apologize for the inconvenience." Reference Link

16:08 EDT Houston American Energy increases interest in Colombian project - Houston American Energy announced the acquisition of an additional interest in Hupecol Meta, which owns the 639,405 gross acre CPO-11 block in the Llanos Basin in Colombia, comprised of the 69,128 acre Venus Exploration area, operated by Hupecol, and 570,277 acres which was 50% farmed out to Parex Resources by Hupecol. "In total, the CPO-11 block covers almost 1000 square miles with multiple identified leads and prospects expected to support a multi-well drilling program. Through its membership interest in Hupecol Meta, Houston American now holds an approximately 11% interest in the Venus Exploration area and an approximately 5.5% interest in the remainder of the block. Drilling operations on Houston American's first well in the Venus Exploration area are now ongoing," the company stated.

16:01 EDT SportsMap Tech Acquisition receives noncompliance notice from Nasdaq - SportsMap Tech Acquisition announced that on May 25 it received a notice from the Listing Qualifications Department of Nasdaq stating that the company is not in compliance with Nasdaq Listing Rule 5250 because the company failed to timely file its quarterly report on Form 10-Q for the period ended March 31 and remains delinquent in filing its annual report on Form 10-K for the period ended December 31, 2021 with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the company's securities on Nasdaq.

13:02 EDT Baker Hughes reports U.S. rig count down 1 to 727 rigs - Baker Hughes reports that the U.S. rig count is down 1 from last week to 727 with oil rigs down 2 to 574, gas rigs up 1 to 151 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 270 rigs from last year's count of 457 with oil rigs up 215, gas rigs up 53 and miscellaneous rigs up 2. The U.S. Offshore Rig Count is down 2 to 16, up 2 year-over-year. The Canada Rig Count is up 15 from last week to 103, with oil rigs up 15 to 55, gas rigs unchanged at 48. The Canada Rig Count is up 41 rigs from last year's count of 62, with oil rigs up 27, gas rigs up 14.

13:00 EDT Baker Hughes reports U.S. rig count down 1 to 727 rigs

12:32 EDT VectivBio Holding AG trading halted, volatility trading pause

12:00 EDT Global Blue falls -6.4% - Global Blue is down -6.4%, or -33c to $4.82.

12:00 EDT Big Lots falls -10.3% - Big Lots is down -10.3%, or -$3.15 to $27.50.

12:00 EDT PropertyGuru rises 14.9% - PropertyGuru is up 14.9%, or 99c to $7.64.

11:36 EDT Osisko Development announces NYSE listing - Osisko Development announced that its common shares have commenced trading on the New York Stock Exchange under the symbol "ODV". Consequently, the Company has satisfied the escrow release condition relating to the 34,093,768 subscription receipts of the Company for gross proceeds of $119.4M, which were issued on a non-brokered private placement basis. A portion of the net proceeds of the Offering will be used to fund the cash consideration for the acquisition of Tintic Consolidated Metals LLC, with the remaining funds to be used to advance the development of the Company's mineral assets and for general corporate purposes.

11:02 EDT CIBC raises quarterly dividend to C$0.83 per share - Yesterday, CIBC announced that its board of directors declared a dividend of C$0.83 per share on common shares for the quarter ending July 31, payable on July 28 to shareholders of record at the close of business on June 28. This was an increase in its quarterly common share dividend from C$0.805 per share.

10:51 EDT Twitter board does not accept resignation of Silver Lake's Egon Durban - In a Form 8-K filing, Twitter said, "On May 25, 2022, Twitter held its annual meeting of stockholders. Egon Durban did not receive a majority of the votes cast at the Meeting for his election to the Company's Board of Directors. In accordance with the Company's Corporate Governance Guidelines, in advance of his nomination, Mr. Durban tendered his resignation as a member of the Board, with the effectiveness of such resignation being conditioned upon Mr. Durban not receiving a majority of the votes cast for his election at the Meeting and the Board's acceptance of such resignation. The Board believes that the reason Mr. Durban failed to receive the support of a majority of the votes cast for his reelection to the Board at the Meeting was due to proxy advisory firm voting guidelines, as well as voting policies of certain institutional investors regarding board service limitations. As disclosed in the Company's proxy statement, Mr. Durban serves on the boards of directors of six other publicly traded companies. Following deliberations, on May 26, 2022, the Board determined not to accept the Tendered Resignation in connection with Mr. Durban's agreement to reduce his board service commitment to no more than five public company boards by May 25, 2023. In making its determination, the Board considered the recommendation of the Company's Nominating and Corporate Governance Committee to not accept the Tendered Resignation. The Nominating Committee, in making its recommendation to the Board, considered factors they deemed relevant, including Mr. Durban's appointment to the Board pursuant to a March 9, 2020 agreement between the Company and funds affiliated with Silver Lake, whereby Silver Lake has the right to designate one nominee on the Company's slate of nominees for election to the Board. The Nominating Committee further considered Mr. Durban's other commitments in light of his overall contributions to the Board and was confident that Mr. Durban has sufficient capacity to fulfill his fiduciary duties to the Company's stockholders. The Board considers Mr. Durban a highly effective member and believes that he brings to the Board an unparalleled operational knowledge of the industry, a unique perspective, and an invaluable skill set and experience with mergers and acquisitions. The Board noted that Mr. Durban has strengthened its ability to oversee the Company's long-term value creation strategy and effectively govern its implementation. Further, Mr. Durban is consistently well-prepared, engaged and a meaningful contributor to Board meetings and discussions. While the Board does not believe that Mr. Durban's other public company directorships will become an impediment if such engagements were to continue, Mr. Durban's commitment to reduce his board service commitment to five public company boards by the Remediation Date appropriately addresses the concerns raised by stockholders with regard to such engagements. Accordingly, the Board has reached the determination that accepting Mr. Durban's Tendered Resignation at this time is not in the best interests of the Company. Mr. Durban did not participate in the deliberations by the Nominating Committee or the Board regarding whether to accept the Tendered Resignation."

10:12 EDT Sunlands Technology Group (Class A ADS) trading resumes

10:07 EDT Sunlands Technology Group (Class A ADS) trading halted, volatility trading pause

10:00 EDT American Eagle falls -7.5% - American Eagle is down -7.5%, or -$1.05 to $12.97.

10:00 EDT Dell Technologies rises 14.2% - Dell Technologies is up 14.2%, or $6.22 to $50.16.

10:00 EDT Solo Brands rises 19.5% - Solo Brands is up 19.5%, or 89c to $5.45.

09:53 EDT Procaps Group SA trading resumes

09:48 EDT Instill Bio Inc trading halted, volatility trading pause

09:47 EDT American Eagle falls -9.5% - American Eagle is down -9.5%, or -$1.33 to $12.69.

09:47 EDT Gap falls -14.2% - Gap is down -14.2%, or -$1.58 to $9.54.

09:47 EDT Solo Brands rises 13.2% - Solo Brands is up 13.2%, or 60c to $5.16.

09:46 EDT Knightscope deploys additional Bay Area security robot - Knightscope announced another Autonomous Security Robot deployment in the San Francisco Bay Area with a Fortune 500 American clothing and accessories retailer. The K5 ASR is patrolling outside of its California headquarters to deter and detect trespassers and help keep employees and visitors safe.

09:45 EDT Sarissa condemns 'poor' corporate governance at Alkermes - Sarissa Capital Management LP made a statement regarding Alkermes. The statement says, in part: "Sarissa is disappointed that our discussions with Richard Pops, CEO of Alkermes, regarding the nominations of directors was abruptly ended by the company's sudden announcement of its slate of nominees for the upcoming annual meeting. We were shocked that this occurred because no independent director has reached out or talked to us. This behavior represents some of the worst corporate governance that we have seen in our many years of advocacy for sound corporate governance and for companies to be run in the interests of shareholders. Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago. Notably, in the last five years (2017-2021), despite growing revenues and having revenues over $1 billion, Alkermes has consistently operated at a net loss. During the same period, Alkermes has underperformed the IBB by approximately 130%. Despite the company's history of poor performance under Pops, the board in its oversight role appears not to take its independence and fiduciary duties seriously. Despite Sarissa being one of Alkermes' largest shareholders and our history of shareholder value creation, the governance committee made no effort at all to speak with us or our candidates. The independent directors' recommendation of a board slate for election should take into account the views of shareholders. Accordingly, governance committees generally feel they have a duty to understand why a shareholder wants to nominate directors and at least speak to those candidates. At Sarissa, we have nominated directors to many companies, and we cannot think of any instance in which independent directors did not speak directly with us. We believe it is possible the entire process at Alkermes was controlled by Pops who manipulated the rest of the board members. Independent directors should run the nomination process and determine the board slate. As Alkermes and shareholders are aware, we have a proven track record of creating shareholder value. We will not stand by to witness this offense on corporate governance, the egregious neglect of shareholder interests and Pops destroying further shareholder value."

09:37 EDT Gap trading resumes

09:31 EDT Kintara Therapeutics announces first European site activation in Phase 2/3 trial - Kintara Therapeutics announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial for glioblastoma, titled Glioblastoma Adaptive Global Innovative Learning Environment, has activated its first European site, University Hospital Zurich in Zurich, Switzerland. GBM AGILE is currently active at 44 clinical sites in the United States and Canada as of May 26, 2022. GBM AGILE is a patient-centered, Phase 2/3 adaptive platform trial evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara's arm of the study. GCAR plans to enroll 150-200 patients in the Kintara arm of the study at over 40 sites in the U.S. and Canada with potential to increase this total to 65 clinical trial centers worldwide.

09:29 EDT S&P Global Ratings upgrades Ranger Oil - Ranger Oil Corporation announced that S&P Global Ratings upgraded its issuer credit rating on the Company to 'B' with a stable outlook and moved the debt rating of its senior unsecured debt to 'B+'.

09:20 EDT Aerojet Rocketdyne CEO addresses Warren Lichtenstein's recent commentary - Eileen Drake, the CEO of Aerojet Rocketdyne, issued the following statement addressing Executive Chairman and conflicted stockholder Warren Lichtenstein's recent commentary: "The claims in Mr. Lichtenstein's recent press release would be laughable and comically misleading, but for the fact they are part of a distracting and value-destroying proxy fight combined with scorched-earth litigation tactics that he and his hedge fund (Steel Partners) initiated in late January and continue to pursue to this day, all to advance his personal agenda and financial gain to the detriment of the Company and its stockholders. His litany of misguided rantings include: Blaming Ms. Drake for an independent investigation that was based on his own misconduct at the Company, one that was approved by ALL of the non-executive directors of the board, led by an esteemed national law firm and that resulted in a strong reprimand for Mr. Lichtenstein's behavior. Failing to mention that Mark Tucker, his proposed CEO replacement and recently identified director nominee, is also a Steel Partners paid consultant. Blaming Ms. Drake for the senior executives who recently left Aerojet Rocketdyne following the extreme pressure and demands Mr. Lichtenstein imposed on them as part of his attempted takeover. Blaming Ms. Drake for purported performance failures, when in fact Aerojet Rocketdyne outperformed during Ms. Drake's tenure compared to the period before Ms. Drake's appointment while subject to Mr. Lichtenstein's oversight. Conveniently overlooking the fact that Ms. Drake was named THE MUSES 2022 Woman of the Year, along with many other recognitions for her successful stewardship of the Company. Together with an apparent inability to cite any third party recognitions of Mr. Lichtenstein's accomplishments at the Company, which is not surprising given the Company's underperformance before Ms. Drake's appointment. Ignoring the many millions of dollars the Company has paid to Mr. Lichtenstein for his distant oversight as Executive Chair, evidenced by the fact that he rarely, if ever, visits the Company's offices, not to mention his poor management and oversight of the Company's now under-funded pension fund. As Mr. Lichtenstein said, the record speaks for itself."

09:16 EDT SciSparc announces pricing of $10M private placement - SciSparc announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit, priced at-the-market under Nasdaq rules. Each unit and pre-funded unit consist of one ordinary share and two non-tradable warrants each exercisable for one ordinary share for $2.57. The warrants have a term of five years from the issuance date. No actual units will be issued in the offering. The offering is expected to close on or about June 1, 2022, subject to the satisfaction of customary closing conditions.

09:04 EDT AstraZeneca initiates dosing of first patient in anifrolumab trial - The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis.

09:01 EDT Lowe's raises quarterly dividend 31% to $1.05 from 80c per share - Payable August 3 to shareholders of record as of July 20.

08:45 EDT Aesther Healthcare Acquisition Corp trading resumes

08:19 EDT Aesther Healthcare Acquisition, United Gear & Assembly enter merger agreement - Aesther Healthcare Acquisition announced that it has entered into an Agreement and Plan of Merger with United Gear & Assembly. Upon closing of the transaction, United Gear will be a wholly-owned subsidiary of Aesther. In addition, Aesther will change its name to EVGT LTD and its common stock and warrants are expected to be listed on Nasdaq, under the symbols "EVGT" and "EVGTW," respectively, upon closing of the transaction. United Gear, a subsidiary of United Stars Holdings will be led by United Stars chairman, Roger West, as its Executive Chairman, and Todd Romanoski as its President and CEO. With more than 515 unique parts produced in 2022, United Gear has developed a broad global customer base for which it designs and manufactures high precision gears for multiple large end markets, with key customers already in place. These high-growth, multi-billion dollar markets include the $287.4B electric vehicles market, for which United Gear supplies parts for Lucid; the $3.8T automotive market, for which United Gear supplies electric vehicle parts for Volvo, HUSCO, Dana and GM, and legacy customers TREMEC and Tsubaki; the $7.3T construction market, for which United Gear supplies parts for Allison Transmission, Toyota, Ingersol Rand, and Caterpillar; the $1.8T mining market, with customers Cummins, GKN Driveline and Caterpillar; and the $11.0T U.S agriculture market, for which United Gear works with John Deere.

08:15 EDT PDC Energy sees Q2 total production 240,000-250,000 BOE/day - The Company's second quarter outlook remains generally unchanged as it expects to invest nearly $260 -$290 million in the second quarter of 2022 and deliver total production and oil production of 240,000-250,000 Boe per day and 79,000-83,000 Bbls per day, respectively.

08:13 EDT PDC Energy raises 2022 oil, gas production view 235-250 Mboe/d - Previous view 225-240 Mboe/d. Raises oil production view 78-83 Mbbl/d from 74-81 Mbbl/d. Narrows oil and gas capital investments view $950M-$1B from $900M-$1B. President and Chief Executive Officer Bart Brookman commented, "We are excited to roll out our updated 2022 budget, which not only delivers top tier FCF generation of $1.7 billion each of the next two years, but also allows us outstanding shareholder returns of at least $1 billion annually. In the face of significant inflation, our operating teams have done a tremendous job innovating, driving additional efficiencies, and ensuring our capital budget remains at or below $1 billion. As we streamline our operations, the Great Western acquisition provides the Company with additional scale and high value inventory with increased shareholder returns. I want to thank the PDC team for their efforts to efficiently integrate operations according to plan and welcome all the new employees who have joined PDC."

08:10 EDT Aesther Healthcare Acquisition Corp trading halted, news pending

08:08 EDT Nisun International announces Nasdaq notice of non-compliance - Nisun International announced that on May 25, it received a letter from The Nasdaq Stock Market notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the company's Class A common shares was below $1.00 per share for a period of 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the company has a compliance period of 180 calendar days, or until November 21, 2022, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the company's common shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance with the minimum bid price requirement by November 21, 2022, the company may be eligible for an additional 180 calendar day grace period.

08:06 EDT Inovio announces survival results from trial of INO-5401+INO-9012+Libtayo - INOVIO announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo in the treatment of newly diagnosed glioblastoma, including encouraging median overall survival data from fifty-two subjects. Median OS duration in unmethylated MGMT (Cohort A) was 17.9 months. Median OS data in MGMT Methylated patients (Cohort B) are being presented for the first time, at a median of 32.5 months, which compares favorably to historical comparisons (23.2-25 months). Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. The data from this study was selected to be presented in an oral presentation by Dr. David Reardon on Monday, June 6, 2022, at the 2022 American Society of Clinical Oncology at the McCormick Place Convention Center in Chicago, Illinois.

08:04 EDT Bolt Biotherapeutics to present ex vivo data on myeloid cell landscape - Bolt Biotherapeutics announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022. The poster is titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates." Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates and BDC-3042, designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody ISAC candidates.

08:03 EDT Immutep publishes abstracts on TACTI-002, TACTI-003 - Immutep is pleased to announce new interim data from Part A of the Phase II TACTI-002 trial in 1st line NSCLC has been published in an abstract at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting. Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the Company. Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that will be presented as a Trial-in-Progress Poster Presentation at ASCO 2022.

08:02 EDT Immersion files patent infringement complaint against Meta Platforms - Immersion (IMMR) announced that it has filed a complaint against Meta Platforms (FB) in the United States District Court for the Western District of Texas. The complaint alleges that Meta's augmented and virtual reality, or AR/VR, systems, including the Meta Quest 2, infringe six Immersion patents that cover various uses of haptic effects in connection with such AR/VR systems. Immersion is seeking to enjoin Meta from further infringement and to recover a reasonable royalty for such infringement.

08:01 EDT Global Crossing Airlines appoints Helane Becker to advisory board - Global Crossing Airlines Group is pleased to announce the appointment of Helane Becker to its Advisory Board. Becker is a managing director of Cowen and senior research analyst who covers airlines, air freight, and aircraft leasing.

07:53 EDT Hibbett drops 7% to $47.50 after Q1 results miss estimates

07:33 EDT NFI Group's ADL announces delivery of 1000th BYD ADL electric bus - NFI Group (NFYEF) subsidiary Alexander Dennis Limited and BYD UK (BYDDY) jointly announced that their electric vehicle partnership has delivered its 1000th zero-emission bus. ADL and BYD UK have been working in partnership since 2015. The BYD ADL Enviro400EV double decker was part-funded by the Scottish Government and handed over to Stagecoach Bluebird in Aberdeen during Scottish Bus Week in the presence of the Scottish Government's Minister for Just Transition, Employment and Fair Work.

07:30 EDT EHang forms partnership with Charoen Pokphand for AAV, UAM operations - EHang Holdings (EH) announced it has formed a strategic partnership with Charoen Pokphand Group (CHPFF) with an intent to establish a joint venture in Thailand for AAV sales and urban air mobility operations. The two parties intend to fully leverage their respective expertise and resources in a long-term comprehensive collaboration on AAV product sales and marketing, regulatory compliance, business development, infrastructure deployment, talent cultivation, and so on, for future UAM operations and introduce the safe, autonomous and sustainable air mobility technology and solutions to Thailand as well as more overseas markets. The parties expect that their strategic collaboration will unleash UAM solutions' value-creating potential across multiple industries. The partnership opens up cross-sector cooperation opportunities for C.P. Group and EHang and sets up a solid foundation for potential use cases for EHang AAVs in various scenarios such as in aerial sightseeing, cargo transportation, last-mile delivery, city air taxi, smart city management, etc. in Thailand and beyond.

07:14 EDT Farmland Partners acquires farm in Illinois, sells farm in South Dakota - Farmland Partners announced it closed two transactions this week - an acquisition in Illinois and a disposition in South Dakota. The 78.5-acre row crop farm in Illinois was purchased on Tuesday for $685,000. It is the company's first acquisition in Will County, which is in the northeastern part of the state and sits in the Chicago Metropolitan Statistical Area, as designated by the U.S. Census Bureau. On Wednesday, FPI sold 1,690 acres of South Dakota farmland for $7.8M to the farmer who was renting the land. The transaction resulted in an approximately 16% gain for the company.

07:12 EDT Barrick Gold announces social, skills, infrastructure investment in Tanzania - Barrick Gold announced that it would spend $6 for every ounce of gold sold by its two mines in the country on improving healthcare, education, infrastructure and access to potable water in the communities around them. At the same time, it has committed up to $70 million for investment in value-adding national projects, including mining-related training, skills development and scientific facilities at Tanzanian universities, as well as road infrastructure. This is in accordance with the conditions underlying Barrick's framework agreement with the government, which included the establishment of their Twiga joint venture. Twiga oversees a 50/50 split of the economic benefits generated by the mines as well as their management. Barrick has spent more than $1.9 billion in taxes, salaries and payments to local businesses over the past two years. At least 73% of the mines' goods and services are sourced locally and they give preference to the employment of Tanzanian nationals. Barrick has to date also paid the government $140 million of the $300 million settlement included in the framework agreement.

07:10 EDT BeyondSpring presents clinical data on CIN, NSCLC Programs - BeyondSpring announced three poster presentations at the American Society of Clinical Oncology Annual Meeting being held June 3-7, 2022, in Chicago, Illinois. Presentation highlights: Chemotherapy-induced neutropenia: Real-world CMS data showed that week 1 after chemotherapy still presents unmet medical needs with febrile neutropenia risk, even with prophylactic G-CSF, among patients with breast cancer after high FN-risk chemo; DUBLIN-3: Improved quality of life in plinabulin/docetaxel combination vs. docetaxel alone in 2nd/3rd line EGFR-wild type NSCLC patients using the validated EORTC QLQ C30 and QLQ LC13 questionnaires; DUBLIN-3: Subgroup analysis in patients with non-squamous, EGFR-wild type, 2nd/3rd line NSCLC from the global Phase 3 trial showed a superior survival benefit of 2.6 months in median overall survival in the plinabulin/docetaxel combination vs. docetaxel alone, HR=0.75, p=0.023. Title: Real-world effectiveness of prophylactic granulocyte colony-stimulating factor early and late in the cycle for the prevention of febrile neutropenia among patients with breast cancer after high FN-risk chemotherapy: The relative FN risk in Week 1 vs. Weeks 2-3 of the cycle with G-CSF is unknown. It was analyzed compared with no G-CSF in the real-world setting with high FN risk chemotherapy. Using a CMS database of administrative claims representing 100% of fee-for-service Medicare, an analysis of breast cancer patients who initiated docetaxel, doxorubicin or cyclophosphamide monotherapy or combination therapy between 01/01/2015 - 12/31/2019 was performed. Prophylactic G-CSF was highly effective for the prevention of FN in weeks 2-3 but relatively ineffective in Week 1 of cycle 1 in the real-world setting. This represents an unmet medical need in Week 1 of the cycle with SoC G-CSF. Title: DUBLIN-3 results on quality of life in second/third-line EGFR-wild type NSCLC patients receiving docetaxel with or without plinabulin using the validated EORTC QLQ C30 and QLQ LC13 questionnaires: In the ITT population of the DUBLIN-3 Phase 3 trial, the plinabulin/docetaxel combination had better quality of life versus docetaxel alone in second/third-line EGFR-wild type NSCLC patients. EORTC QLQ C30 and QLQ LC13 scores were collected at baseline, Day 1 and Day 8 of each cycle. Mean change from baseline in cumulative C30 and LC13 were overall in favor of plinabulin/docetaxel. LC13 items in favor of plinabulin/docetaxel vs docetaxel alone were items 31, 36 and 37. Title: Subgroup analysis in patients with non-squamous, EGFR-wild type, second/third-line NSCLC from the global phase 3 trial DUBLIN-3 with the plinabulin/docetaxel combination versus Doc alone: With PD-1/PD-L1 inhibitors moving to first line in NSCLC, 2nd/3rd line NSCLC represents a severe unmet medical need, dominated by docetaxel-based therapies with greater than40% severe neutropenia and limited survival. In the ITT population of the DUBLIN-3 Phase 3 trial, the plinabulin/docetaxel combination had superior efficacy, safety and quality of life versus docetaxel alone in EGFR-wild type, second/third-line NSCLC patients. In this subgroup analysis of the non-squamous subgroup, the addition of plinabulin to docetaxel was superior to docetaxel alone for efficacy and safety.

07:07 EDT iClick Interactive Asia withdraws FY22 outlook - The company said, "In view of episodic resurgences of the COVID-19 pandemic since the first quarter of 2022 and various disease control measures implemented by the government in various regions in China including Beijing and Shanghai, substantial uncertainties remain around the macroeconomic conditions and client demand, which have and will continue to materially affect our client on-boarding and solution implementation. Relaxation of restrictions on economic and social life may lead to new cases, which may lead to the re-imposition of restrictions. As a result, the duration of COVID-19's disruption on our business and the resulting financial and operational impact on us cannot be reasonably estimated at this time. The extent to which the COVID-19 pandemic may further impact our business and financial performance will depend on future developments, which are highly uncertain and largely beyond our control. Given the evolving nature of the COVID-19 pandemic and disease control measures implemented by government, currently we are unable to forecast with reasonable accuracy the full duration, magnitude, and pace of recovery across our markets. Therefore, we are withdrawing our financial guidance for full year 2022 announced in our previous earnings release on March 24, 2022. We will continue to closely monitor the impact of the pandemic on our operations and financial results, and provide an update when there is improved visibility."

07:05 EDT Farmmi announces 1-for-25 ordinary share consolidation - Farmmi announced that at the company's shareholder meeting on May 14, the proposed consolidation of the company's ordinary shares was approved at the ratio of one-for-twenty-five with the market effective date of May 31. The objective of the share consolidation is to enable the company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq. Beginning with the opening of trading on May 31, the company's ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol "FAMI" but under a new CUSIP Number, G33277123.

07:03 EDT Instil Bio announces IND clearance of ITIL-306 - Instil Bio announced IND clearance by the U.S. Food and Drug Administration of ITIL-306, Instil's first genetically-engineered Costimulatory Antigen Receptor TIL therapy, as well as the presentation of supporting in vivo CoStAR data at the 2022 ASCO Annual Meeting. ITIL-306 is an autologous TIL cell therapy engineered with a novel and proprietary Costimulatory Antigen Receptor that is activated by folate receptor alpha to provide robust costimulatory signals. CoStAR builds on the key advantages of native TILs, including their polyclonal anti-tumor reactivity, to enhance the cytokine release, cytolytic activity, and proliferation of TILs in the tumor microenvironment. The design of Instil's first-in-human Phase 1 study of ITIL-306 will enroll patients with non-small cell lung cancer, ovarian cancer, and renal cell carcinoma and will start with a dose of one billion CoStAR-transduced TILs. Manufacturing for ITIL-306 will occur at Instil's Tarzana, California manufacturing facility. The poster presentation at the 2022 ASCO Annual Meeting will outline findings from studies evaluating anti-FOLR1 CoStAR T cells in vitro as well as a mouse solid tumor model in vivo. The poster presentation highlights results demonstrating enhanced T cell function and tumor control by CoStAR-modified T cells. Importantly, improved tumor control in a mouse solid tumor model occurred without exogenous IL-2 administration, supporting a clinical CoStAR-TIL regimen free of high-dose IL-2. CoStAR T cells showed limited upregulation of PD-1 after target exposure and demonstrated improved persistence in vivo.

06:50 EDT Pinduoduo jumps 10% to $46.00 after Q1 results beat estimates

06:36 EDT LyondellBasell announces $5.20 per share special dividend - LyondellBasell announced its board of directors has declared a special dividend of $5.20 per share and a quarterly dividend of $1.19 per share. The quarterly dividend represents a 5% increase over the company's first quarter 2022 dividend. The special and quarterly dividends will both be paid on June 13 to shareholders of record as of June 6 with an ex-dividend date of June 3.

06:30 EDT GlaxoSmithKline says China approves Cervarix two-dose vaccine schedule for girls - GSK plc announced that a two-dose schedule for its HPV vaccine Cervarix has been approved by China's NMPA for girls aged 9 to 14. "With this approval, Cervarix is the first imported two-dose HPV vaccine for this age group in mainland China. The NMPA authorisation of the two-dose regimen adds China to two-dose approvals in approximately 100 countries, including the European Union, Asia, Africa, and Latin America2-7. The three-dose schedule remains on the label for girls and women aged 15-45 years in China," the company stated.

06:03 EDT Tanzanian Gold changes name to 'TRX Gold Corporation' - TRX Gold Corporation is pleased to announce that effective today at market open, the company will begin trading as TRX Gold Corporation. The company's common shares will continue trading on the Toronto Stock Exchange under its current ticker symbol "TNX" and on the New York Stock Exchange under its current ticker symbol "TRX". The new CUSIP of the common shares is 87283P109 and the new ISIN is CA87283P1099.

05:12 EDT The Very Good Food Company receives noncompliance notification from Nasdaq - The Very Good Food Company was notified on May 20 by Nasdaq that since the company had not yet filed its annual report on Form 20-F for the year ended December 31, 2021, it was no longer in compliance with Nasdaq's Listing Rules for continued listing.

05:05 EDT AbbVie announces results from three trials evaluating upadacitinib published - AbbVie announced The Lancet published results from three pivotal Phase 3 clinical trials - U-ACHIEVE induction, U-ACCOMPLISH and U-ACHIEVE maintenance - evaluating upadacitinib in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. Data from the three studies formed the basis of the company's application for approval by regulatory agencies. The publication reports the efficacy and safety results of the two induction studies and a maintenance study evaluating clinical remission and endoscopic improvement with oral upadacitinib versus placebo over 8 weeks and 52 weeks, respectively. The use of upadacitinib for ulcerative colitis is not approved in the European Union and its safety and efficacy remain under review by the global health authorities.